Candesartan (8 mg/d) was administered for 2 weeks to eight patients with essential hypertension to investigate the effect of an angiotensin II receptor antagonist on insulin sensitivity. The effect of candesartan on sodiumretaining action and the activation of pressor systems by hyperinsulinaemia, which might be related to pressor mechanisms in essential hypertension, was also investigated in this study. In patients with essential hyperten-
Introduction
Insulin resistance and accompanying hyperinsulinaemia have recently been reported to play an important role in the occurrence and maintenance of essential hypertension, dyslipidaemia, and arteriosclerosis. [1] [2] [3] [4] Several kinds of hypotensive drugs, such as thiazide diuretics and ␤-blockers, have been reported to impair insulin sensitivity. 5, 6 Conversely, it has been recognised that angiotensinconverting enzyme (ACE) inhibition improves insulin sensitivity in essential hypertension, [5] [6] [7] [8] suggesting an important role for the suppression of angiotensin II generation.
There have been very few reports on the effect of angiotensin receptor antagonists on insulin sensitivity in patients with essential hypertension. Paolisso et al 9 reported that losartan improves insulinmediated glucose uptake through an increase in non-oxidative glucose metabolism and blood flow in hypertensive patients. Moan et al 10 found that losartan improves insulin sensitivity in patients with severe essential hypertension, but has neutral effects on insulin sensitivity in those with mild essential hypertension. 11 Laakso et al 12 indicated that losartan is metabolically neutral, and has no significant adverse effect on the glucose metabolism. Thus, the effect of losartan on insulin sensitivity is still controversial. This study was designed to elucidate the effect of an angiotensin II receptor antagonist, candesartan, on insulin sensitivity and on the pressor Correspondence: Dr Katsuhiro Higashiura, The Second Department of Internal Medicine, Sapporo Medical University School of Medicine, S-1 W-16, Chuo-ku, Sapporo 060-0061, Japan sion, candesartan restored insulin sensitivity to the level of that in normotensive subjects. Candesartan treatment attenuated the sodium-retaining action of hyperinsulinaemia. These findings suggest that inhibition of angiotensin II action by candesartan can improve insulin sensitivity and inhibit the sodiumretaining action associated with hyperinsulinaemia in essential hypertension.
mechanism of hyperinsulinaemia in essential hypertension.
Patients and methods
This study was done in accordance with the Declaration of Helsinki (1983). The study protocol was approved by the ethics committee of Sapporo Medical University. All patients gave written or verbal informed consent for all procedures.
Eight patients with essential hypertension (WHO stage I-II; age (mean ± s.d.), 46.5 ± 4.1 years), and 18 age and body mass index-matched normotensive controls (aged 45.9 ± 4.1 years) who did not have liver diseases, renal diseases or diabetes mellitus were studied. All patients were admitted to the hospital and were given a constant diet containing 120 mmol of sodium and 75 mmol of potassium per day.
After a 2-week control period, a 2-h euglycaemic hyperinsulinaemic glucose clamp was done, according to the method of DeFronzo et al, 13 to estimate in vivo sensitivity for insulin in essential hypertension and in normotension. In the glucose clamp study, a continuous infusion of insulin was administered for 2 h, during which the plasma glucose concentration was held constant at basal level by a variable infusion of glucose, using a model STG-22 artificial endocrine pancreas (Nikkiso, Tokyo, Japan). The mean rate of glucose infusion (M-value, given as milligrams of glucose per square metre of body surface area per minute during the last 30 min of the clamp) was used as an indicator of insulin sensitivity.
The eight patients with essential hypertension
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were each treated with 8 mg of candesartan daily for 2 weeks. Determination of insulin sensitivity by the glucose clamp method was then repeated in all patients. Before and after the clamp, mean blood pressure, heart rate, creatinine clearance, urinary sodium excretion, blood sugar level, plasma insulin level, plasma renin activity, plasma aldosterone concentration, and plasma noradrenaline level were measured in each subject. Blood sugar was measured by the glucose oxidase method. Serum or urinary sodium levels were determined by the ion electrode method. Plasma insulin, plasma renin activity, and plasma aldosterone were measured by radio immunoassay techniques (Insulin RIA bead, Dainabot, Tokyo, Japan; Gamma Cord, Baxter Healthcare, Tokyo, Japan; and Aldosterone RLA kit II, Dainabot, respectively). Plasma noradrenaline was measured by the high-performance liquid chromatographytrihydroxyindol method. All data were expressed as mean ± s.e.m. Student's t-test was used to determine significance in comparison of paired and unpaired data. A P value of less than 0.05 was considered to indicate significance.
Results

Effect of candesartan on insulin sensitivity
Mean blood pressure was significantly higher in the patients with essential hypertension (109.2 ± 4.8 mm Hg, P Ͻ 0.001) compared to the normotensive subjects (90.0 ± 1.7 mm Hg). There were no differences in fasting blood sugar and insulin levels between patients with essential hypertension (96.3 ± 13.0 mg/dl and 4.3 ± 0.6 mU/L, respectively) and normotensive subjects (96.2 ± 1.6 mg/dl and 2.4 ± 1.6 mU/L, respectively). With the glucose clamp method, however, the M-value in essential hypertension (152.9 ± 7.7 mg/m 2 per minute) was significantly lower (P Ͻ 0.001) than that in normotension (215.5 ± 50.7 mg/m 2 per minute). A 2-week period of treatment with candesartan reduced blood pressure significantly from 109.2 ± 4.8 mm Hg to 93.2 ± 5.5 mm Hg (P Ͻ 0.01) in patients with essential hypertension. There was no significant change in fasting blood sugar and plasma insulin levels between the control and candesartan treatment period in essential hypertension (from 96.3 ± 13.0 to 94.4 ± 9.5 mg/dl, and from 4.3 ± 0.6 to 3.5 ± 0.3 mU/L, respectively). Insulin sensitivity assessed by the Mvalue increased significantly from 152.9 ± 7.7 mg/m 2 per minute to 216.6 ± 25.5 mg/m 2 per minute (P Ͻ 0.05) (Figure 1 ) after treatment with candesartan.
Effect of candesartan on renal sodium handling and pressor system activities induced by hyperinsulinaemia
No significant change was found in mean blood pressure and heart rate in the control period during the clamp technique in either the normotension or the essential hypertension groups. Although plasma aldosterone concentration showed no significant change, significant increases in plasma noradrena- line and plasma renin activity were observed in the essential hypertension group during the clamp technique. Urinary sodium excretion decreased significantly during insulin infusion by the clamp technique in patients with essential hypertension (Figure 2) .
After candesartan treatment in the essential hypertension group, the decreases in urinary sodium excretion during hyperinsulinaemia were significantly suppressed (Figure 2 ). Increases in plasma noradrenaline and plasma renin activity during hyperinsulinaemia were observed, even with candesartan treatment (Table 1 ).
Figure 2
Urinary sodium excretion (UNaV) before and after the glucose clamp (GC) in the control period and the period of treatment with candesartan in eight patients with essential hypertension. *P Ͻ 0.01 vs before clamp. 
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Discussion
We have shown that the angiotensin II receptor antagonist candesartan improves insulin resistance in patients with essential hypertension, through ACE inhibition. Several possible mechanisms of improved insulin sensitivity by angiotensin receptor antagonism have been suggested. These include vasodilation, which increases the blood flow in skeletal muscles; activation of the glucose transporter and its translocation from an intracellular membrane compartment to a plasma membrane fraction; and suppression of noradrenaline release induced by angiotensin II antagonism. It has been shown that the dose-response curve between insulin action and increased leg blood flow is shifted to the right in insulin-resistant patients. 14 This suggests that the vasodilator action of insulin is attenuated and that blood flow in feeding capillaries is decreased in an insulin-resistant state. It has also been reported that capillary density and the diffusion distance from the capillaries to the muscle cells play a significant role in determining in vivo insulin action. 15 Thus, vasodilation by an angiotensin receptor antagonist may lead to increased blood flow in the capillaries of skeletal muscles, resulting in improved insulin sensitivity.
It is well recognised that translocation of glucose transporter 4 (GLUT 4) from an intracellular membrane compartment to a plasma membrane fraction is a key pathway of insulin-mediated glucose uptake in insulin-sensitive tissues. It has been proposed that there is an impairment of translocation of GLUT 4 by insulin, and that this impairment is one of the mechanisms of insulin resistance in diabetic model rats. 16 Recent data have provided evidence that inhibition of the angiotensin II receptor improves translocation of GLUT 4 from an intracellular membrane compartment to a plasma membrane fraction. 17 Regarding the suppression of noradrenaline release induced by angiotensin II antagonism, basal plasma noradrenaline levels and those induced by hyperinsulinaemia were not suppressed by candesartan administration in this study. The suppression of noradrenaline release therefore does not seem to be a mechanism.
As possible pressor mechanisms of insulin resistance-hyperinsulinaemia, renal sodium-retaining action and sympathetic nervous system-stimulating action by hyperinsulinaemia have been proposed. In our previous study, 18 we showed that infused insulin markedly reduced renal sodium excretion, and that plasma noradrenaline and plasma renin activity were significantly increased during the clamp technique in both normotension and essential hypertension groups. In this study, with candesartan treatment, the decreases in urinary sodium excretion during hyperinsulinaemia induced by a glucose clamp were suppressed in patients with essential hypertension. This might be explained by the suppression of angiotensin II action through increased renal blood flow, suppressed renal tubular sodium reabsorption by angiotensin II, or suppressed aldosterone synthesis. These natriuretic actions by candesartan may balance renal tubular sodium reabsorption by the direct action of insulin. The action of candesartan on renal sodium handling may also be related to the chronic hypotensive effect of this agent. Although no placebo was used in this study, it has well been recognised that candesartan has an effect of lowering blood pressure in patients with essential hypertension. The control period consisted of a 2-week hospitalisation to stabilise blood pressure. We could not completely exclude the possibility of placebo effect, but it would be of little effect on blood pressure and insulin sensitivity.
Impaired glucose tolerance, dyslipidaemia, and hypertension are established cardiovascular risk factors. Resistance to insulin-mediated glucose uptake and the resulting hyperinsulinaemia may possibly contribute to the pathogenesis of these disorders. It has also been recently suggested that insulin resistance and hyperinsulinaemia may be associated with hypertensive arteriosclerotic complications, including coronary artery disease, [1] [2] [3] [4] and that metabolic side effects should be considered when selecting antihypertensive agents. 19, 20 These results suggest that angiotensin II antagonists could be useful antihypertensive drugs in essential hypertension patients with insulin resistance.
